Clinical trials
Hemophilia B trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 8 |
| Not yet recruiting | 3 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 7 |
| Pfizer | 5 |
| Bioverativ Therapeutics Inc. | 2 |
| First Affiliated Hospital of Wannan Medical College | 2 |
| Genzyme, a Sanofi Company | 2 |
| Bayer | 1 |
| CSL Behring | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Novo Nordisk A/S | 1 |
| Peking University People's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia B | 29 |
| Hemophilia A | 12 |
| Blood Coagulation Disorders | 2 |
| Blood Coagulation Disorders, Inherited | 2 |
| Coagulation Protein Disorders | 2 |
| Critical Illness | 2 |
| Genetic Diseases, Inborn | 2 |
| Genetic Diseases, X-Linked | 2 |
| Hematologic Diseases | 2 |
| Hemorrhage | 2 |
Trials
Showing 26 to 29 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.